Asset Details
Do you wish to reserve the book?
Sequential afatinib and osimertinib in patients with
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sequential afatinib and osimertinib in patients with
Do you wish to request the book?
Sequential afatinib and osimertinib in patients with
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sequential afatinib and osimertinib in patients with
2020
Overview
Final overall survival (OS) and time on treatment analysis of patients with
mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib.
Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory.
Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7–29.9). Median OS was 37.6 months (90% CI: 35.5–41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively.
In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with
mutation-positive NSCLC, especially in Del19-positive patients and Asian patients.
NCT03370770 (
)
Publisher
Future Medicine Ltd
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.